04 December 2021 : Case report
Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy
Unusual or unexpected effect of treatment
Hillary S. Maitland1ABCDEFG*DOI: 10.12659/AJCR.933788
Am J Case Rep 2021; 22:e933788
Figure 1. Platelet count, fostamatinib dose, and avatrombopag dose over time. * Indicates that an approximate date was used.